Roche’s KRAS blocker touts best-in-class NSCLC potential in Phase III trial

Phase 3positivedivarasibPositive

AI Analysis

Summary

Genentech's divarasib, a KRAS blocker developed by Roche, demonstrated best-in-class potential in Phase III trial for NSCLC treatment. The positive data supports the game-changing potential of KRAS-targeting therapies in hard-to-treat cancers.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

divarasib posts positive Phase III trial results in NSCLC with best-in-class potential

Importance:7/10

Sentiment:

0.75

KRAS-targetingNSCLCPhase IIIoncologypositive data

Related Companies

$RHHBY

Read the original article

Published by Clinical Trials Arena on July 2, 2026 10:17 AM

Read Original